KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Equity (2016 - 2025)

Historic Return on Equity for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to 0.54%.

  • Xenon Pharmaceuticals' Return on Equity fell 2800.0% to 0.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54%, marking a year-over-year decrease of 2800.0%. This contributed to the annual value of 0.29% for FY2024, which is 700.0% down from last year.
  • Xenon Pharmaceuticals' Return on Equity amounted to 0.54% in Q3 2025, which was down 2800.0% from 0.44% recorded in Q2 2025.
  • Xenon Pharmaceuticals' Return on Equity's 5-year high stood at 0.14% during Q2 2022, with a 5-year trough of 0.54% in Q3 2025.
  • Moreover, its 5-year median value for Return on Equity was 0.23% (2024), whereas its average is 0.25%.
  • Its Return on Equity has fluctuated over the past 5 years, first surged by 1100bps in 2022, then crashed by -2800bps in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Return on Equity (Quarter) stood at 0.2% in 2021, then increased by 14bps to 0.17% in 2022, then plummeted by -37bps to 0.23% in 2023, then tumbled by -37bps to 0.32% in 2024, then tumbled by -68bps to 0.54% in 2025.
  • Its Return on Equity stands at 0.54% for Q3 2025, versus 0.44% for Q2 2025 and 0.36% for Q1 2025.